Pulmonology Practice Questions

Q: Reactivation of pulmonary tuberculosis always occurs at which location?

Apex of the upper lobe. ### Explanation **1. Why the Apex of the Upper Lobe is Correct:** Reactivation (Secondary) Tuberculosis typically occurs in the **apical and posterior segments of the upper lobes**. The primary physiological reason is the **high oxygen tension ($PO_2$)** found in the lung apices [2]. *Mycobacterium tuberculosis* is an obligate aerobe that thrives in oxygen-rich environments. In a standing individual, the ventilation-perfusion ($V/Q$) ratio is highest at the apex because gravity reduces blood flow more significantly than ventilation. This creates an environment with high alveolar oxygen concentration and relatively poor lymphatic drainage, allowing the dormant bacilli (from a previous primary infection) to proliferate. **2. Why the Other Options are Incorrect:** * **Lower part of the upper lobe / Upper part of the lower lobe (Options A & B):** These areas are the classic sites for **Primary Tuberculosis** (the **Ghon focus**). Primary TB typically affects the subpleural regions of the mid-to-lower lung zones where ventilation is greatest during initial inhalation of the droplet nuclei [1]. * **Lower part of the lower lobe (Option C):** This area has the highest blood flow but the lowest $V/Q$ ratio and lower oxygen tension compared to the apex, making it an unfavorable site for the reactivation of aerobic mycobacteria. **3. Clinical Pearls for NEET-PG:** * **Simon Focus:** These are the initial nodules formed in the lung apices during the hematogenous seeding of primary TB, which later serve as the site for reactivation. * **Assmann Focus:** A term used for the infraclavicular lesion seen in secondary TB. * **Cavitation:** Secondary TB is characterized by caseous necrosis and **cavitation**, which is less common in primary TB (except in immunocompromised patients). * **Imaging:** On a Chest X-ray, look for "infiltrates or cavities in the apical/posterior segments of the upper lobe."

Q: Which of the following components is included in the CURB-65 score?

Severe azotemia. The **CURB-65 score** is a validated clinical prediction rule used to determine the severity of Community-Acquired Pneumonia (CAP) and guide the decision for outpatient vs. inpatient management [1]. ### **Explanation of the Correct Answer** The "U" in CURB-65 stands for **Urea**. Specifically, a blood urea nitrogen (BUN) level **>19 mg/dL (7 mmol/L)** is considered a point [1]. This represents **azotemia**, which reflects systemic inflammation, dehydration, or secondary renal dysfunction due to sepsis. In the context of the options provided, "Severe azotemia" is the only component that aligns with the Urea criteria. ### **Analysis of Incorrect Options** * **A. PaO2 less than 65 mm Hg:** While hypoxia is critical in pneumonia, the CURB-65 score uses **Respiratory Rate (≥30/min)** as its respiratory marker, not PaO2 [1]. (Note: The "65" in the score refers to age, not oxygen levels). * **B. Coagulopathy:** This is a feature of the ATS/IDSA criteria for severe pneumonia (e.g., thrombocytopenia), but it is not a component of the CURB-65 score. * **D. Base deficit (acidosis):** While metabolic acidosis indicates poor perfusion, it is not part of this specific scoring system. ### **High-Yield Facts for NEET-PG** The CURB-65 mnemonic stands for: 1. **C**onfusion (new onset) 2. **U**rea >19 mg/dL (7 mmol/L) 3. **R**espiratory Rate ≥30 breaths/min 4. **B**lood Pressure (Systolic <90 mmHg or Diastolic ≤60 mmHg) 5. **65**: Age ≥65 years [1]. **Clinical Management Pearl:** * **Score 0-1:** Low risk; consider outpatient treatment. * **Score 2:** Moderate risk; consider short-stay inpatient or close outpatient monitoring. * **Score 3-5:** High risk; requires hospitalization (consider ICU for scores 4-5) [1].

Q: Which of the following is the initial management strategy for chronic obstructive pulmonary disease?

Cessation of smoking. **Explanation:** The management of Chronic Obstructive Pulmonary Disease (COPD) focuses on symptom relief, reduction of exacerbations, and slowing disease progression. [1] **Why "Cessation of Smoking" is correct:** Smoking cessation is the **single most effective intervention** and the cornerstone of initial management. It is the only intervention (along with long-term oxygen therapy in hypoxic patients) proven to **slow the rate of decline in FEV1** and reduce mortality. [1], [2] According to the GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines, every patient should be counseled on smoking cessation at every clinical encounter, regardless of the stage of the disease. [1] **Why the other options are incorrect:** * **Anticholinergics (B):** While inhaled bronchodilators (like Tiotropium or Ipratropium) are the mainstay for **symptomatic** management and are often the first-line pharmacological choice, they do not alter the natural history or the decline in lung function as effectively as smoking cessation. [1] * **Aminophylline (A):** This is a methylxanthine with a narrow therapeutic index and significant side effects. It is considered a third-line agent, used only when symptoms persist despite optimal inhaled therapy. [1] * **Oral Steroids (D):** These are used for managing acute exacerbations. Long-term use of oral steroids is discouraged in stable COPD due to a high risk-to-benefit ratio (e.g., osteoporosis, hyperglycemia, and infections). **High-Yield Clinical Pearls for NEET-PG:** * **Most common cause of COPD:** Smoking. * **Only interventions that improve survival:** Smoking cessation and Long-Term Oxygen Therapy (LTOT) for >15 hours/day. [2] * **Vaccination:** All COPD patients should receive the Influenza and Pneumococcal vaccines to prevent exacerbations. * **Diagnosis:** Post-bronchodilator FEV1/FVC ratio < 0.70 is diagnostic. [1]

Q: All of the following are characterized by upper lobe fibrosis except?

Busulfan. **Explanation:** The distribution of pulmonary fibrosis (upper vs. lower lobe) is a high-yield topic in NEET-PG. Most interstitial lung diseases (ILDs) and drug-induced toxicities typically affect the **lower lobes** due to higher blood flow and gravity-dependent deposition. **1. Why Busulfan is the correct answer:** Busulfan is an alkylating agent used in chemotherapy (e.g., for CML). It is a classic cause of **drug-induced pulmonary fibrosis**, which characteristically involves the **lower lobes**. Other drugs following this pattern include Bleomycin, Amiodarone, and Methotrexate. **2. Analysis of Incorrect Options (Upper Lobe Involvement):** * **Silicosis:** A pneumoconiosis caused by silica dust inhalation. It typically presents with nodular opacities and progressive massive fibrosis (PMF) in the **upper lobes** [1]. * **Cystic Fibrosis:** Characterized by thick secretions and recurrent infections (like *Pseudomonas*). It predominantly affects the **upper lobes** with bronchiectasis and secondary fibrosis. * **Histoplasmosis:** Fungal infections (and others like Tuberculosis) have a predilection for the **upper lobes** due to higher oxygen tension, leading to apical scarring and cavitation [2]. **3. High-Yield Clinical Pearls for NEET-PG:** To remember the causes of **Upper Lobe Fibrosis**, use the mnemonic **"SCART"**: * **S:** Silicosis, Sarcoidosis * **C:** Coal Worker's Pneumoconiosis, Cystic Fibrosis [1] * **A:** Ankylosing Spondylitis, Allergic Bronchopulmonary Aspergillosis (ABPA) [2] * **R:** Radiation (if the field is upper lobe) * **T:** Tuberculosis [2] **Lower Lobe Fibrosis** is typically seen in **BAD** conditions: **B**ras (Busulfan/Bleomycin), **A**miodarone/Asbestosis, and **D**rugs/Dermatomyositis/IPF.

Q: In pulmonary embolism, what is the primary risk associated with fibrinolytic therapy?

Risk of haemorrhage. The primary risk associated with fibrinolytic therapy (e.g., Alteplase, Streptokinase) in pulmonary embolism (PE) is **haemorrhage** [1]. Fibrinolytics work by converting plasminogen to plasmin, which enzymatically degrades fibrin clots [2]. However, this process is systemic and non-specific; it dissolves not only the pathological embolus but also protective physiological hemostatic plugs. The most feared complication is **intracranial haemorrhage (ICH)**, occurring in approximately 1-2% of patients, while major bleeding occurs in up to 10% [1]. **Analysis of Options:** * **Option A (Correct):** Haemorrhage is the most significant adverse effect and the primary reason why thrombolysis is reserved only for high-risk (massive) PE [1]. * **Option B (Incorrect):** While thrombolysis improves hemodynamics in massive PE [1], "improved prognosis" is a therapeutic goal/benefit, not a "risk." * **Option C (Incorrect):** Resolution of the emboli is the intended mechanism of action and clinical objective, not a risk. * **Option D (Incorrect):** Thrombolysis does not reduce the risk of recurrence; long-term anticoagulation is required for that purpose [1]. **High-Yield Clinical Pearls for NEET-PG:** 1. **Indication:** Thrombolysis is indicated for **Massive PE** (defined by hemodynamic instability/systolic BP <90 mmHg) [1]. It is generally *not* recommended for low-risk or submassive PE unless there is clinical deterioration. 2. **Absolute Contraindications:** Prior ICH, known structural cerebrovascular lesion, ischemic stroke within 3 months, active internal bleeding, or suspected aortic dissection. 3. **Window:** Benefit is greatest when started within 48 hours of symptom onset but can be effective up to 14 days [1].

Q: What is the typical sequence of symptoms in pulmonary embolism?

Dyspnea, pain, hemoptysis. **Explanation:** Pulmonary Embolism (PE) typically presents with a classic triad of symptoms that follow a specific physiological sequence based on the progression of the embolic event [1]. **1. Why Option C is Correct:** The sequence **Dyspnea → Chest Pain → Hemoptysis** reflects the clinical progression of PE: * **Dyspnea:** This is usually the first and most common symptom. It occurs suddenly due to a reflex increase in ventilation and an increase in alveolar dead space (V/Q mismatch) [1]. * **Chest Pain:** As the embolus lodges, it causes pleural irritation or localized ischemia. This is typically pleuritic in nature [1]. * **Hemoptysis:** This is a later sign, occurring when the obstruction leads to pulmonary infarction or hemorrhage into the alveolar spaces [1]. **2. Why Other Options are Incorrect:** * **Options A & B:** While a low-grade fever can occur in PE due to inflammation/infarction, it is rarely the presenting or primary symptom. Fever is more characteristic of infectious processes like pneumonia. * **Option D:** Purulent sputum is a hallmark of bacterial pneumonia or bronchiectasis, not PE. PE is associated with a dry cough or hemoptysis, but never purulent expectoration. **3. High-Yield Clinical Pearls for NEET-PG:** * **Most Common Symptom:** Tachypnea (Sign) and Dyspnea (Symptom). * **ECG Findings:** Most common is **Sinus Tachycardia** [2]. The classic **S1Q3T3** pattern is specific but seen in only <20% of cases [2]. * **Gold Standard Investigation:** CT Pulmonary Angiography (CTPA). * **Chest X-ray:** Usually normal, but look for **Westermark sign** (focal oligemia) or **Hampton’s Hump** (wedge-shaped opacity) [2]. * **Wells Score:** Used for clinical probability assessment before ordering a D-dimer or CTPA.

Q: Which of the following conditions may lead to exudative pleural effusions?

Bronchogenic carcinoma. Explanation: Pleural effusions are classified into **transudates** and **exudates** based on Light's Criteria, which reflect the underlying pathophysiology of fluid accumulation [1]. **Correct Answer: D. Bronchogenic Carcinoma** Exudative effusions occur due to inflammation, increased capillary permeability, or lymphatic obstruction. In **Bronchogenic Carcinoma**, the malignancy causes direct pleural involvement, inflammatory cytokine release, and obstruction of lymphatic drainage [1]. This leads to the leakage of proteins and cells into the pleural space. Malignancy is one of the most common causes of exudative effusion, often presenting with hemorrhagic fluid and low glucose levels [1]. **Incorrect Options:** * **A, B, and C (Cirrhosis, Nephrotic Syndrome, CHF):** These are classic causes of **transudative effusions**. * **CHF** increases pulmonary capillary hydrostatic pressure. * **Cirrhosis and Nephrotic Syndrome** lead to hypoalbuminemia, which decreases plasma oncotic pressure. In these conditions, the pleural membranes are intact, but systemic factors alter the pressure gradients, forcing protein-poor fluid into the pleural space. **High-Yield Clinical Pearls for NEET-PG:** * **Light’s Criteria:** An effusion is an **exudate** if it meets at least one: 1. Pleural fluid protein/Serum protein ratio > 0.5 2. Pleural fluid LDH/Serum LDH ratio > 0.6 3. Pleural fluid LDH > 2/3rd the upper limit of normal serum LDH. * **Most common cause of transudate:** Congestive Heart Failure. * **Most common cause of exudate:** Parapneumonic effusion, followed by Malignancy [1]. * **Meigs Syndrome:** A rare triad of benign ovarian tumor (fibroma), ascites, and pleural effusion (usually transudative).

Question 1

Reactivation of pulmonary tuberculosis always occurs at which location?

Accepted Answer

Apex of the upper lobe

Answer

Lower part of the upper lobe

Answer

Upper part of the lower lobe

Answer

Lower part of the lower lobe

Question 2

Which of the following components is included in the CURB-65 score?

Accepted Answer

Severe azotemia

Answer

PaO2 less than 65 mm Hg

Answer

Coagulopathy

Answer

Base deficit (acidosis)

Question 3

Which of the following is the initial management strategy for chronic obstructive pulmonary disease?

Accepted Answer

Cessation of smoking

Answer

Aminophylline

Answer

Anticholinergics

Answer

Oral steroids

Question 4

All of the following are characterized by upper lobe fibrosis except?

Accepted Answer

Busulfan

Answer

Silicosis

Answer

Cystic Fibrosis

Answer

Histoplasmosis

Question 5

In pulmonary embolism, what is the primary risk associated with fibrinolytic therapy?

Accepted Answer

Risk of haemorrhage

Answer

Improved prognosis

Answer

Resolution of massive emboli

Answer

Reduced risk of recurrence

Question 6

What is the typical sequence of symptoms in pulmonary embolism?

Accepted Answer

Dyspnea, pain, hemoptysis

Answer

Fever, pain, dyspnea

Answer

Fever, dyspnea

Answer

Dyspnea, cough, purulent sputum

Question 7

An elderly male, a chronic smoker with 40 pack-years, complains of recurrent difficulty in breathing. A chest X-ray showed abnormalities. Which of the following positions is most comfortable for a patient experiencing difficulty in breathing?

Accepted Answer

All positions are the same in respect to comfort

Answer

Standing

Answer

Sitting

Answer

Lying down

Question 8

Which of the following conditions may lead to exudative pleural effusions?

Accepted Answer

Bronchogenic carcinoma

Answer

Cirrhosis

Answer

Nephrotic syndrome

Answer

Congestive heart failure

Question 9

A patient presents with left hemiplegia and a history of right deep vein thrombosis. What is the most likely cause of hemoptysis in this patient?

Accepted Answer

Pulmonary thromboembolism

Answer

Disseminated intravascular coagulation

Answer

Fat embolism

Answer

Superior vena cava syndrome

Question 10

Which of the following conditions can present with an obstructive pattern on pulmonary function tests in an Interstitial Lung Disease (ILD)?

Accepted Answer

Pulmonary lymphangioleiomyomatosis

Answer

Idiopathic pulmonary fibrosis

Answer

Non-specific interstitial pneumonitis

Answer

Cryptogenic organizing pneumonia

Pulmonology — MCQs

Pulmonology — MCQs

On this page

Practice by Chapter

Want unlimited practice?